Burden and Impact of Reactogenicity among Adults Receiving COVID-19 Vaccines in the United States and Canada: Results from a Prospective Observational Study.

Burden and Impact of Reactogenicity among Adults Receiving COVID-19 Vaccines in the United States and Canada: Results from a Prospective Observational Study.

Publication date: Jan 13, 2024

As SARS-CoV-2 variants continue to emerge, vaccination remains a critical tool to reduce the COVID-19 burden. Vaccine reactogenicity and the impact on work productivity/daily activities are recognized as contributing factors to vaccine hesitancy. To encourage continued COVID-19 vaccination, a more complete understanding of the differences in reactogenicity and impairment due to vaccine-related side effects across currently available vaccines is necessary. The 2019nCoV-406 study (n = 1367) was a prospective observational study of reactogenicity and associated impairments in adults in the United States and Canada who received an approved/authorized COVID-19 vaccine. Compared with recipients of mRNA COVID-19 booster vaccines, a smaller percentage of NVX-CoV2373 booster recipients reported local and systemic reactogenicity. This study’s primary endpoint (percentage of participants with ≥50% overall work impairment on ≥1 of the 6 days post-vaccination period) did not show significant differences. However, the data suggest that NVX-CoV2373 booster recipients trended toward being less impaired overall than recipients of an mRNA booster; further research is needed to confirm this observed trend. The results of this real-world study suggest that NVX-CoV2373 may be a beneficial vaccine option with limited impact on non-work activities, in part due to the few reactogenicity events after vaccination.

Open Access PDF

Concepts Keywords
2019ncov absenteeism
Canada BNT162b2
Mrna COVID-19
Vaccination mRNA-1273
NVX-CoV2373
presenteeism
reactogenicity
real-world evidence
SARS-CoV-2
work impairment

Semantics

Type Source Name
disease MESH COVID-19
disease VO Canada
disease VO vaccination
disease VO vaccine
disease VO authorized COVID-19 vaccine
disease VO NVX-CoV2373
disease VO USA
drug DRUGBANK Coenzyme M
disease MESH infection
disease VO Comirnaty
disease VO Ad26.COV2.S
disease VO CoVLP
disease VO dose
disease VO vaccine strain
disease VO vaccinated
disease VO effective
disease MESH erythema
disease MESH lymphadenopathy
disease MESH arthralgia
disease VO vaccine dose
disease VO organization
drug DRUGBANK Serine
disease IDO history
disease MESH allergic reaction
disease MESH emergency
disease VO time
disease VO population
disease IDO country
drug DRUGBANK Dimercaprol
drug DRUGBANK Tacrine
disease VO age
disease MESH Education level
disease IDO production
disease MESH Hypertension
disease VO injection
disease VO ANOVA
disease IDO symptom
disease VO frequency
disease IDO site
disease MESH Infectious Diseases
disease MESH long COVID
disease VO report
disease VO company
disease IDO blood
disease VO immunization
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Isoxaflutole
disease VO primary vaccination

Original Article

(Visited 1 times, 1 visits today)